Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Efficacy of desloratadine in intermittent allergic rhinitis: a GA(2)LEN study Bousquet J; Bachert C; Canonica GW; Mullol J; Van Cauwenberge P; Bindslev Jensen C; Fokkens WJ; Ring J; Keith P; Lorber R; Zuberbier TAllergy 2009[Oct]; 64 (10): 1516-1523BACKGROUND: The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines proposed a classification for allergic rhinitis based on the duration of symptoms (intermittent, persistent) rather than on the time of allergen exposure (seasonal, perennial). There is no placebo-controlled, randomized clinical trial on intermittent allergic rhinitis (IAR) to date. Desloratadine (DL) is recommended for the first-line treatment of seasonal and perennial allergic rhinitis. OBJECTIVES: To assess the efficacy and safety of DL in subjects with IAR based on the ARIA classification. METHODS: Patients over 12 years of age with IAR were assessed over 15 days of treatment with DL 5 mg once daily (n = 276) or placebo (n = 271). The primary endpoint was the AM/PM reflective total 5 symptom score (T5SS). Secondary endpoints included AM/PM instantaneous T5SS and individual symptoms, therapeutic response, symptom severity by visual analogue scale, and quality-of-life. RESULTS: The mean reduction of AM/PM reflective T5SS was significantly greater with DL than with placebo over 15 days (-3.01 vs-2.13, P < 0.001) and on each individual day (P < 0.05). Mean AM instantaneous T5SS was reduced significantly with DL compared to placebo as early as day 2 (-1.84 vs-0.89; P < 0.001). The therapeutic response and improvement in quality-of-life were significantly greater with DL than with placebo (P < 0.001 for each). The frequency of treatment-related adverse events was low and similar between DL (7.2%) and placebo (7.0%). CONCLUSIONS: This is the first large trial to show that treatment can be effective in IAR. Desloratadine was effective and safe.|*Histamine H1 Antagonists, Non-Sedating/administration & dosage/adverse effects/therapeutic use[MESH]|Adult[MESH]|Double-Blind Method[MESH]|Female[MESH]|Humans[MESH]|Loratadine/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use[MESH]|Male[MESH]|Middle Aged[MESH]|Quality of Life[MESH]|Rhinitis, Allergic, Perennial/*drug therapy/physiopathology[MESH]|Rhinitis, Allergic, Seasonal/*drug therapy/physiopathology[MESH]|Severity of Illness Index[MESH]|Time Factors[MESH]|Treatment Outcome[MESH]|Young Adult[MESH] |